Oct 28, 2024
Lilly declares fourth-quarter 2024 dividend
Oct 25, 2024
Lilly's EBGLYSS(TM) (lebrikizumab-lbkz) demonstrated meaningful improvement in skin clearance and itch relief in the majority of patients with moderate-to-severe atopic dermatitis who discontinued dupilumab
Oct 23, 2024
Lilly's Kisunla(TM) (donanemab-azbt) Receives Marketing Authorization in Great Britain for the Treatment of Mild Cognitive Impairment and Mild Dementia Due to Alzheimer's Disease in Adult Patients Who Are Apolipoprotein E E4 Heterozygotes or Non-Carriers
Oct 16, 2024
Survey reveals 8 in 10 Americans with ulcerative colitis struggle to find a public restroom during emergencies
Oct 16, 2024
Lilly confirms date and conference call for third-quarter 2024 financial results announcement
Oct 14, 2024
Lilly reports one-year histologic outcomes in Phase 3 study of mirikizumab compared to ustekinumab for Crohn's disease
Oct 02, 2024
Lilly announces new $4.5 billion site - the Lilly Medicine Foundry - to drive innovation in drug production and make medicines for clinical trials
Sep 25, 2024
New data show Lilly's EBGLYSS(TM) (lebrikizumab-lbkz) provided sustained disease control for up to three years in more than 80% of adults and adolescents with moderate-to-severe atopic dermatitis
Sep 24, 2024
Lilly's Kisunla(TM) (donanemab-azbt) Approved in Japan for the Treatment of Early Symptomatic Alzheimer's Disease
Sep 12, 2024
Lilly expands manufacturing footprint in Ireland with $1.8 billion investment
Sep 10, 2024
Once-weekly dose of insulin efsitora alfa delivers A1C reduction consistent with the most advanced daily insulin in people with type 2 diabetes
Sep 10, 2024
With once-a-week dosing, insulin efsitora alfa delivers similar A1C reduction compared to daily insulin in adults with type 1 diabetes
Sep 09, 2024
Lilly appoints Lucas Montarce as executive vice president and chief financial officer
Sep 05, 2024
In a first-of-its-kind fixed dose study, once weekly insulin efsitora alfa leads to A1C reduction similar to daily insulin
Sep 04, 2024
Lilly and EVA Pharma collaborate to expand access to baricitinib in low- to middle-income countries
Aug 27, 2024
Lilly releases Zepbound® (tirzepatide) single-dose vials, expanding supply and access for adults living with obesity
Aug 22, 2024
Lilly to participate in Morgan Stanley 22nd Annual Global Healthcare Conference
Aug 20, 2024
Tirzepatide reduced the risk of developing type 2 diabetes by 94% in adults with pre-diabetes and obesity or overweight
Aug 16, 2024
Lilly Completes Acquisition of Morphic to Improve Outcomes and Expand Options for People Living with Inflammatory Bowel Disease
Aug 16, 2024
Lilly announces retirement of Marschall S. Runge from its Board of Directors